Teal Health

We are honored to be among the founding members of the Biospecimen Management Consortium (BMC), which will work to develop best practices and standards across the industry; streamline biospecimen lifecycle operations and data management; and shape regulatory policy. At Teal, we are passionate about innovating in the women's health space and advancing clinical research. 

As we announced last month, our nationwide SELF-CERV study completed enrollment ahead of schedule, while exceeding initial enrollment projections. This was made possible because of the exceptional teams at our study sites and the amazing women who raised their hands to participate. Additionally, we had great partners, like Slope to ensure the operations and logistics ran smoothly. Our very own Trena Depel recently participated in Slope Clinical’s Advisory meeting to discuss the value that using Slope’s biospecimen sample management platform brought to our study. Slope is dedicated to driving best practices in biospecimen management and was an invaluable partner to the rapid and successful enrollment of SELF-CERV, with over 1,000 samples to manage. Our clinical sites loved the simplicity of ordering supplies, logging samples, and managing shipments using the Slope platform, and Teal Health appreciated the real-time metrics to understand enrollment and sample movement across our 17 clinical sites and multiple labs. We will certainly be using Slope for our future studies as well. Here are a few highlights of the benefits we measured.

Thank you Fast Company for showcasing our at-home cervical cancer screening device and our telehealth service. There is so much potential to increase screening rates and reduce cervical cancer incidence in the US, using at-home screening, virtual provider support, and care navigation to in-person follow-up care (when appropriate). We are excited for the journey ahead! https://lnkd.in/g4qnqXck

We're proud to partner with Evvy and many other companies as part of the #EqualResearchDay Collaborative this year. Addressing the gender health gap requires a collective effort, and while our work is just beginning, it's incredibly inspiring to see the dedication and energy committed to this shared mission. #womenshealth #genderhealthgap #womensresearch

The good news keeps on coming! Last week, we announced our FDA Breakthrough Designation for our at-home self-collect cervical cancer screening device and yesterday, Roche and BD announced they have received FDA approval for their in-clinic self-collect cervical cancer screening methods. Our Breakthrough Designation grants us priority review with the FDA once we submit our final study data, and the in-clinic approval is an important first step in helping to bring at-home screening through the FDA. Our clinical trial was run on both the Roche and BD Primary HPV assays. We are thrilled for Roche and BD and congratulate them on this important work to expand screening options for women and people with a cervix. #womenshealth #tealhealth #femtech https://lnkd.in/ep7CVdKG

World Changing Ideas! Thank you Fast Company for recognizing Teal Health for our efforts to increase access and improve the cervical cancer screening experience in the US. As we have shared before, self-collect cervical cancer screening is already being used in 17 countries across the globe and proving to be instrumental in increasing screening rates and decreasing cervical cancer incidence. We are honored to be among the efforts in the US to activate REAL POSITIVE CHANGE for this critical life-saving screening. #womenshealth #femtech https://lnkd.in/dnZETN9G

We’re proud to be part of Teal Health’s journey to create a more comfortable pap smear 🔬 Kara Egan, one of the cofounders behind Teal, wanted to make cervical cancer screening more accessible. The current process involves an uncomfortable procedure that must be performed in a doctor's office. The company came to IDEO for help designing an applicator and testing experience that would allow users to safely and accurately collect a sample at home and be inclusive for anyone with a cervix. The first challenge was to create the wand. The IDEO team set out to design functional, testable prototypes to make sure the idea was viable, and incorporate diverse voices into the research process, including trans, minority, and disabled women. They used a 3-D printer to create multiples of every prototype, autoclaves to make sure that the designs they were creating were sterile, and leaned into shapes women are already used to, like the cylindrical shape of a tampon. In January 2023, Teal raised an $8.8 million seed round from Serena Ventures, Emerson Collective, and Metrodora, and later that year, launched a nationwide clinical trial with leading health organizations including Johns Hopkins University, Yale University, the University of Colorado, Washington University, and others to support FDA submission and approval. It’s an enormous step toward its North Star: saving lives by catching cervical cancer earlier. Read more about the collaborative process: https://lnkd.in/gnHs9Hpt

Our CEO and Co-Founder, Kara Egan, took the stage last night as a panelist in the Cancer Diagnostics Revolution session, to talk cervical cancer prevention through at-home self-collect screening. #MIGlobal

Today, we announced our FDA Breakthrough Designation and the record enrollment of our clinical trial. Two major milestones for the Teal Health team. To celebrate and acknowledge the tremendous work it has taken to get to this point, our CEO and Co-Founder, Kara Egan, reflects on these milestones and the incredible small, but mighty team that is making it all happen. Read more here: https://bit.ly/3QxIQtG Spoiler: The Breakthrough work has been led by our clinical team, which is a powerhouse of 4 full-time individuals setting up and managing 17 sites across the country, countless analytical studies, and navigating FDA submissions and requirements. It’s unbelievable what they and the rest of the team have accomplished. #womenshealth #femtech

Today is a BIG DAY FOR WOMEN’S HEALTH! Our Teal Wand at-home cervical cancer screening device has been granted FDA Breakthrough Designation, putting it on an accelerated path to market based on our ability to increase access to this life-saving screening. This designation was given based on the strength of the interim results from our clinical trial. AND, on top of that, we’ve since finished our clinical trial in record time, so when we say at-home cervical cancer screening is one step closer to becoming a reality in the US, we really mean it! See our full release: https://bit.ly/4bowgoy #womenshealth #femtech